Literature DB >> 6872621

Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.

C Choi, A S Bayer, N K Fujita, K Lam, L B Guze, T T Yoshikawa.   

Abstract

Right-sided infective endocarditis due to Pseudomonas aeruginosa was induced in 130 rabbits. Animals received either: (1) no therapy (controls); (2) standard-dose amikacin (AMK) (15 mg/kg/day) plus ticarcillin (300 mg/kg/day), or (3) high-dose AMK (20 or 25 mg/kg/day) plus ticarcillin, for 20 days. Animals in each treatment group were evaluated at 10 days after therapy for bacteriologic relapse. Both standard- and high-dose AMK regimens significantly decreased mortality and Pseudomonas aeruginosa vegetation titers versus controls (p less than 0.01, p less than 0.05, respectively). Despite significantly higher serum AMK levels at 25 mg/kg/day, there was no significant difference in mean vegetation titers, percent of vegetations sterilized, or posttherapy bacteriologic relapse in the three treatment groups. AMK at 20 or 25 mg/kg/day (but not at 15 mg/kg/day) significantly reduced the incidence of pulmonary infarction versus untreated controls (p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872621     DOI: 10.1159/000238213

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

Authors:  M Backo; E Gaenger; A Burkart; Y L Chai; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci.

Authors:  A S Bayer; J Yih; L Hirano
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

3.  Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.

Authors:  A S Bayer; D C Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

4.  Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.

Authors:  A S Bayer; P Lindsay; J Yih; L Hirano; D Lee; I K Blomquist
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

5.  Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.

Authors:  A S Bayer; D Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.

Authors:  A S Bayer; L Hirano; J Yih
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

7.  Bactericidal interactions of a beta-lactam and beta-lactamase inhibitors in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive overproducer of type Id beta-lactamase.

Authors:  A S Bayer; M Selecky; K Babel; L Hirano; J Yih; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.